Clinical Phenotyping and Disease Specific Sampling to Identify Non-coding RNAs for Human Therapeutics in PAD
临床表型分析和疾病特异性采样,以鉴定用于 PAD 人类治疗的非编码 RNA
基本信息
- 批准号:10538629
- 负责人:
- 金额:$ 72.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgeAmputationAreaArteriesAtherosclerosisBioinformaticsBiologicalBiological MarkersBiological TestingBloodBlood VesselsBlood flowCardiovascular systemCell DeathCell SurvivalCellsClassificationClinicalClinical ResearchDLEU2 geneDNADataDiagnosisDiseaseDisease modelEndothelial CellsEvolutionFaceFutureGenderGenesGenomeHealthHindlimbHomologous GeneHumanImpairmentIn VitroInflammatoryInjuryIntermittent ClaudicationInvestigationIschemiaLegMALAT1 geneMacrophageMedicalMicroRNAsMolecular BiologyMorbidity - disease rateMusMuscleMyoblastsOrganOryctolagus cuniculusPain in lower limbPathway interactionsPatientsPerfusionPeripheral arterial diseasePhenotypePlasmaPoly APolyadenylationProliferatingProteinsRNARNA analysisResearchResistanceRestRibosomal RNARiskRisk FactorsRodent ModelSamplingScientistSkeletal MuscleSourceSurgeonTUG1 geneTestingTherapeuticTimeTissuesTranslatingTubeUlcerUnited StatesUniversitiesUntranslated RNAUp-RegulationValidationVascular blood supplyVirginiaWalkingWestern WorldWorkartery occlusionbiobankclinical phenotypeclinically relevantcohortcritical limb Ischemiadifferential expressiondisease phenotypedisorder controlexperiencehuman diseaseimprovedin vitro testingin vivoin vivo Modelinsightischemic injurylimb ischemiamammalian genomemanmortalitymouse modelmyogenesisnovelperipheral bloodpreclinical studypublic health relevanceresponse to injurysexsuccesstherapeutic candidatetranscriptome sequencingtranslational scientist
项目摘要
Abstract
Peripheral arterial disease (PAD) is one of the major complications of systemic atherosclerosis where arterial
occlusions result in two major clinical manifestations: leg pain with walking/reduced walking ability (a condition
termed intermittent claudication, IC) or critical limb ischemia (CLI) with leg pain at rest, ischemic ulcers, and
patients that face a >10% risk/year of major amputation. No medical therapy exists to improve perfusion to the
ischemic limb in PAD and there remains a clear need to develop new treatments. The central dogma of
molecular biology states that DNA makes RNA and RNA makes protein. However, the vast majority of the
mammalian genome does not encode proteins. There are two types of non-coding RNAs: micro-RNA (miR)
and long non-coding (lncRNA) RNAs. The diversity of miRs across species is far greater than encoded genes
and lncRNAs are an order of magnitude more diverse that miRs; this necessitates that strategies study human
disease. To that end, this proposal brings together a translational cardiovascular scientist who studies PAD
and whose work has included micro-RNAs (Annex), a research scientist who focuses on in-vitro and in-vivo
models of PAD (Ganta), a translational scientist who studies skeletal muscle adaptability to injury and has
developed an unparalleled biobank of human PAD tissues (McClung), as well as a computational biologist
(Keene) to provide bioinformatics analysis of RNA sequencing data. The central hypothesis of this proposal
states that condition specific sampling based on insights into the clinical disease condition from well-
phenotyped humans, bioinformatics analysis, and disease specific non-clinical testing will unlock non-coding
RNA novel human therapeutics. To that end, the Specific Aims are: 1: Identify miRs for therapeutic
modulation by determining differential expression in plasma across subjects with intermittent
claudication (IC) and critical limb ischemia (CLI) patients and age/sex-matched non-PAD control
subjects. Determine whether the ischemic skeletal muscle from the most symptomatic ischemic leg
demonstrates elevated expression of the miR. Candidate miR's will be examined through in-vitro studies in
PAD relevant conditions, through in-vivo efficacy. 2. Identify lncRNAs for modulation by determining the
differential expression of lncRNA in calf muscle from non-PAD and PAD (both IC and CLI) patients.
We will first look for lncRNA's that are up-regulated in PAD (IC and CLI) and will then examine whether up-
regulation occurs differentially (IC or CLI). In a new cohort, we will examine predictions form an initial list of
candidate lncRNAs and will determine whether target up-regulation also occurs in blood. 3) Utilize mouse
models of HLI that recapitulate the “major” differential for the IC vs. CLI designation in the human
condition to identify additional candidate lncRNAs that may be conserved from mouse to man and
serve as therapeutic candidates.
摘要
周围动脉疾病(PAD)是系统性动脉粥样硬化的主要并发症之一。
闭塞导致两种主要的临床表现:腿部疼痛伴行走/行走能力下降(一种情况
称为间歇性跛行(IC)或严重肢体缺血(CLI),伴有休息时腿痛、缺血性溃疡和
面临每年10%的重大截肢风险的患者。目前还没有药物治疗来改善心脏的血流灌注。
PAD中的肢体缺血,显然仍需要开发新的治疗方法。的核心教条
分子生物学认为DNA制造核糖核酸,核糖核酸制造蛋白质。然而,绝大多数人
哺乳动物基因组不编码蛋白质。有两种类型的非编码RNA:Micro-RNA(MiR)
和长的非编码(LncRNA)RNA。不同物种的MIR的多样性远远大于编码的基因
与miRs相比,lncRNAs的多样性要高出一个数量级;这就需要战略研究人类
疾病。为此,这项提议汇集了一位研究PAD的翻译心血管科学家
他的工作包括microRNAs(附件),一位专注于体外和体内研究的科学家
PAD模型(甘塔),一位研究骨骼肌对损伤的适应性的翻译科学家,
开发了一个无与伦比的人类PAD组织生物库(McClung),以及一位计算生物学家
(Keene)提供RNA测序数据的生物信息学分析。这项提议的核心假设是
规定根据对井中临床疾病状况的洞察进行特定采样-
表型人类、生物信息学分析和特定疾病的非临床测试将解锁非编码
核糖核酸新人类疗法。为此,具体目标是:1:确定用于治疗的微循环
通过确定间歇性疾病受试者血浆中的差异表达来调节
跛行(IC)和严重肢体缺血(CLI)患者和年龄/性别匹配的无PAD对照
研究对象。确定缺血骨骼肌是否来自症状最严重的缺血小腿
显示miR的表达升高。候选人的miR将通过体外研究在
PAD相关条件下,通过体内疗效观察。2.通过确定要调制的lncRNA
LncRNA在非PAD和PAD(IC和CLI)患者小腿肌肉中的差异表达
我们将首先寻找在PAD(IC和CLI)中上调的lncRNA,然后检查是否上调-
监管发生的方式不同(IC或CLI)。在新的队列中,我们将检查来自以下初始列表的预测
候选的lncRNAs,并将确定靶标上调是否也发生在血液中。3)利用鼠标
HLI模型,概括了人类IC与CLI名称的“主要”区别
识别额外的候选lncRNA的条件,这些候选lncRNA可能在老鼠和人之间保守
作为治疗的候选对象。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Machine Learning Approach to Predict In-Hospital Mortality in Patients Admitted for Peripheral Artery Disease in the United States.
- DOI:10.1161/jaha.122.026987
- 发表时间:2022-10-18
- 期刊:
- 影响因子:5.4
- 作者:Zhang, Donglan;Li, Yike;Kalbaugh, Corey Andrew;Shi, Lu;Divers, Jasmin;Islam, Shahidul;Annex, Brian H.
- 通讯作者:Annex, Brian H.
Dynamic Multiscale Regulation of Perfusion Recovery in Experimental Peripheral Arterial Disease: A Mechanistic Computational Model.
- DOI:10.1016/j.jacbts.2021.10.014
- 发表时间:2022-01
- 期刊:
- 影响因子:0
- 作者:Zhao C;Heuslein JL;Zhang Y;Annex BH;Popel AS
- 通讯作者:Popel AS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRIAN H ANNEX其他文献
BRIAN H ANNEX的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRIAN H ANNEX', 18)}}的其他基金
Clinical Phenotyping and Disease Specific Sampling to Identify Non-coding RNAs for Human Therapeutics in PAD
临床表型分析和疾病特异性采样,以鉴定用于 PAD 人类治疗的非编码 RNA
- 批准号:
10319539 - 财政年份:2020
- 资助金额:
$ 72.38万 - 项目类别:
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery Disease
外周动脉疾病中的抗血管生成 VEGF165b 和 VEGFR1 信号传导
- 批准号:
10312030 - 财政年份:2019
- 资助金额:
$ 72.38万 - 项目类别:
Precision Medicine for Therapeutic Angiogenesis in Peripheral Arterial Disease: Targeting of the IL21R Pathway
外周动脉疾病治疗性血管生成的精准医学:靶向 IL21R 通路
- 批准号:
10219892 - 财政年份:2019
- 资助金额:
$ 72.38万 - 项目类别:
Precision Medicine for Therapeutic Angiogenesis in Peripheral Arterial Disease: Targeting of the IL21R Pathway
外周动脉疾病治疗性血管生成的精准医学:靶向 IL21R 通路
- 批准号:
10457261 - 财政年份:2019
- 资助金额:
$ 72.38万 - 项目类别:
MicroRNA 93 in Peripheral Arterial Disease
MicroRNA 93 在外周动脉疾病中的作用
- 批准号:
8896862 - 财政年份:2014
- 资助金额:
$ 72.38万 - 项目类别:
A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease
外周动脉疾病基因治疗的生物工程方法
- 批准号:
9249087 - 财政年份:2014
- 资助金额:
$ 72.38万 - 项目类别:
Reuse of ZD4054 for patients with symptomatic PAD
对有症状的 PAD 患者重复使用 ZD4054
- 批准号:
8685367 - 财政年份:2013
- 资助金额:
$ 72.38万 - 项目类别:
Reuse of ZD4054 for patients with symptomatic PAD
对有症状的 PAD 患者重复使用 ZD4054
- 批准号:
8599139 - 财政年份:2013
- 资助金额:
$ 72.38万 - 项目类别:
Systems Biology of Angiogenesis: from Molecules to Therapy
血管生成的系统生物学:从分子到治疗
- 批准号:
7290922 - 财政年份:2006
- 资助金额:
$ 72.38万 - 项目类别:
Systems Biology of Angiogenesis: from Molecules to Therapy
血管生成的系统生物学:从分子到治疗
- 批准号:
7249586 - 财政年份:2006
- 资助金额:
$ 72.38万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 72.38万 - 项目类别:
Directed Grant